Preliminary phase III efficacy and safety of alemtuzumab vs chlorambucil as front-line therapy for patients with progressive B-cell chronic lymphocytic leukemia (BCLL).

被引：0
|
作者：
Hillmen, P.
Skotnicki, A.
Robak, T.
Jaksic, B.
机构：
[1] Gen Infirm, Leeds Teaching Hosp NHS Trust, Leeds LS1 3EX, W Yorkshire, England
[2] Jagiellonian Univ, Coll Med, Krakow, Poland
[3] Kopernik Mem Hosp, Lodz, Poland
[4] Clin Hosp, Zagreb, Croatia
[5] Med Univ Lublin, Lublin, Poland
[6] Genzyme, Boston, MA USA
[7] Univ Hosp, Brno, Czech Republic
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：339S / 339S
页数：1
相关论文
共 50 条
  • [31] Bendamustine versus chlorambucil in treatment-naive patients with B-cell chronic lymphocytic leukemia (B-CLL): Results of an international phase III study
    Knauf, Wolfgang Ulrich
    Lissichkov, Toshko
    Aldaoud, Ali
    Herbrecht, Raoul
    Liberati, Anna Marina
    Loscertales, Javier
    Juliusson, Gunnar
    Dittrich, Christian
    Merkle, Karlheinz
    BLOOD, 2007, 110 (11) : 609A - 609A
  • [32] Combined schedule of fludarabine and alemtuzumab followed by maintenance with low-dose alemtuzumab is effective for patients with progressive B-cell chronic lymphocytic leukemia.
    Kowal, M
    Nowak, W
    Nowaczynska, A
    Dmoszynska, A
    Skotnicki, AB
    BLOOD, 2005, 106 (11) : 343B - 344B
  • [33] Pharmacokinetics of alemtuzumab in combination with fludarabine in patients with relapsed or refractory B-cell chronic lymphocytic leukemia
    Elter, Thomas
    Kilp, Julia
    Borchmann, Peter
    Schulz, Holger
    Hallek, Michael
    Engert, Andreas
    Haematologica-The Hematology Journal, 2009, 94 (01): : 150 - 152
  • [34] Maintenance alemtuzumab in refractory B-cell chronic lymphocytic leukemia patients: Updated data.
    Thieblemont, C
    Houot, R
    Toure, BA
    Traulle, C
    Michallet, AS
    Bouafia, F
    Espinouse, D
    Salles, G
    Coiffier, B
    BLOOD, 2005, 106 (11) : 340B - 340B
  • [35] Incidence of second neoplasia in patients with B-cell chronic lymphocytic leukemia treated with chlorambucil maintenance chemotherapy
    Callea, Vincenzo
    Brugiatelli, Maura
    Stelitano, Caterina
    Gentile, Massimo
    Nobile, Francesco
    Morabito, Fortunato
    LEUKEMIA & LYMPHOMA, 2006, 47 (11) : 2314 - 2320
  • [36] Efficacy and Safety of Front-Line Venetoclax and Rituximab (VenR) for the Treatment of Young Patients with Chronic Lymphocytic Leukemia and an Unfavorable Biologic Profile. Preliminary Results of the Gimema Study 'Veritas'
    Mauro, Francesca Romana
    Reda, Gianluigi
    Arena, Valentina
    Trentin, Livio
    Coscia, Marta
    Sportoletti, Paolo
    Laurenti, Luca
    Gaidano, Gianluca
    Marasca, Roberto
    Orsucci, Lorella
    Murru, Roberta
    Stelitano, Caterina
    Ilariucci, Fiorella
    Mannina, Donato
    Massaia, Massimo
    Rigolin, Gian Matteo
    Scarfo, Lydia
    Marchetti, Monia
    Levato, Luciano
    Tani, Monica
    Arcari, Annalisa
    Musuraca, Gerardo
    Deodato, Marina
    Galieni, Piero
    Califano, Catello
    Gottardi, Daniela
    Liberati, Anna Marina
    Pietrasanta, Daniela
    Molica, Stefano
    Cassin, Ramona
    Visentin, Andrea
    Vitale, Candida
    Lapietra, Gianfranco
    Della Starza, Irene
    De Propris, Maria Stefania
    Raponi, Sara
    Nanni, Mauro
    Del Giudice, Ilaria
    Giuliani, Giorgia
    Vignetti, Marco
    Guarini, Anna
    Albano, Francesco
    Neri, Antonino
    Cuneo, Antonio
    Foa, Robin
    BLOOD, 2020, 136
  • [37] Alemtuzumab is effective in the treatment of patients with advanced, heavily pretreated B-cell chronic lymphocytic leukemia.
    Fiegl, M
    Hopfinger, G
    Jaeger, G
    Fridrik, M
    Zojer, N
    Walla, B
    Andel, J
    Schmid, FX
    Weisz, H
    Mayer, P
    Buchel, J
    Greil, R
    BLOOD, 2003, 102 (11) : 358B - 358B
  • [38] Oral cladribine as primary therapy for patients with B-cell chronic lymphocytic leukemia
    Juliusson, G
    Christiansen, I
    Hansen, MM
    Johnson, S
    Kimby, E
    ElmhornRosenborg, A
    Liliemark, J
    JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (07) : 2160 - 2166
  • [39] Safety, efficacy and pharmacokinetics of humanized anti-CD52 monoclonal antibody alemtuzumab in Japanese patients with relapsed or refractory B-cell chronic lymphocytic leukemia
    Ishizawa, Kenichi
    Fukuhara, Noriko
    Nakaseko, Chiaki
    Chiba, Shigeru
    Ogura, Michinori
    Okamoto, Akihiko
    Sunaga, Yoshinori
    Tobinai, Kensei
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2017, 47 (01) : 54 - 60
  • [40] Reconstitution of the T cell repertoire following treatment with alemtuzumab in patients with B-cell chronic lymphocytic leukemia (B-CLL).
    Rezvany, MR
    Tehrani, MJ
    Karlsson, C
    Lundin, J
    Rabbani, H
    Mellstedt, K
    Österborg, A
    BLOOD, 2005, 106 (11) : 837A - 837A
12345